Extracellular vesicles

Extracellular vesicles (CARMEV) for prevention of heart failure (continuation)

The overall goal is to develop extracellular vesicles (EVs) from bone marrow MSCs
to inhibit I/R injury after myocardial infarction (MI) -> heart failure prevention

Time period: 11/2021 – 11/2023

Lead: Karl-Henrik Grinnemo, Uppsala University Hospital

Involved partners: Uppsala University Hospital, Uppsala University, AstraZeneca.

EVs from BM-MSCs (patented technology) inhibit apoptosis of cardiomyocytes, stimulate angiogenesis and preserve the myocardial function including the extracellular matrix structure after ischemia-reperfusion injury in mice.

Work plan:

  • dose-response assays, characterize the biologically active EV preparations
  • confirm the safety of the EV product in animal experiments and human in vitro tests (biodistribution assays, complement activation assays, coagulation assay)
  • generation of a final well-characterized EV product under GMP conditions.
  • initiate contact with the Swedish MPA (Läkemedelsverket).